Breakthrough SARS-CoV-2 infections after COVID-19 immunization

Abstract

As no vaccines are 100% effective at preventing illness, COVID-19 vaccine breakthrough cases are expected. We here aim to review the most recent literature on COVID-19 vaccine breakthrough infections. SARS-CoV-2 breakthrough infections are, in general, rare. Age may still be a factor in SARS-CoV-2 infections in immunized individuals.

Get full access to this article

View all access options for this article.

References

Tavilani

, Abbasi

, Kian Ara

, . COVID-19 vaccines: current evidence and considerations. Metabol Open 2021;12:100124.doi:10.1016/j.metop.2021.100124http://www.ncbi.nlm.nih.gov/pubmed/34541483

Hotez

, Nuzhath

, Callaghan

, . COVID-19 vaccine decisions: considering the choices and opportunities. Microbes Infect 2021;23:104811.doi:10.1016/j.micinf.2021.104811http://www.ncbi.nlm.nih.gov/pubmed/33744495

Hall

, Foulkes

, Charlett

, . SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (siren). Lancet 2021;397:1459–69.doi:10.1016/S0140-6736(21)00675-9http://www.ncbi.nlm.nih.gov/pubmed/33844963

Tande

, Pollock

, Shah

, . Impact of the coronavirus disease 2019 (COVID-19) vaccine on asymptomatic infection among patients undergoing Preprocedural COVID-19 molecular screening. Clin Infect Dis 2022;74:59–65.doi:10.1093/cid/ciab229

Keehner

, Horton

, Pfeffer

, . SARS-CoV-2 infection after vaccination in health care workers in California. N Engl J Med 2021;384:1774–5.doi:10.1056/NEJMc2101927http://www.ncbi.nlm.nih.gov/pubmed/33755376

Inc. JB . FDA Briefing document. Janssen Ad26.COV2.S vaccine for the prevention of COVID-19, 2021.

El Chaar

, King

, Galvez Lima

. Are black and Hispanic persons disproportionately affected by COVID-19 because of higher obesity rates? Surg Obes Relat Dis 2020;16:1096–9.doi:10.1016/j.soard.2020.04.038http://www.ncbi.nlm.nih.gov/pubmed/32522406

Tirupathi

, Muradova

, Shekhar

, . COVID-19 disparity among racial and ethnic minorities in the US: a cross sectional analysis. Travel Med Infect Dis 2020;38:101904.doi:10.1016/j.tmaid.2020.101904http://www.ncbi.nlm.nih.gov/pubmed/33137491

Self

, Tenforde

, Rhoads

, . Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021. MMWR Morb Mortal Wkly Rep 2021;70:1337–43.doi:10.15585/mmwr.mm7038e1http://www.ncbi.nlm.nih.gov/pubmed/34555004

10.

Dos Santos

. Impact of virus genetic variability and host immunity for the success of COVID-19 vaccines. Biomed Pharmacother 2021;136:111272.doi:10.1016/j.biopha.2021.111272http://www.ncbi.nlm.nih.gov/pubmed/33486212

11.

Duffy

. Why are RNA virus mutation rates so damn high? PLoS Biol 2018;16:e3000003.doi:10.1371/journal.pbio.3000003http://www.ncbi.nlm.nih.gov/pubmed/30102691

12.

Prevention CfDCa. . About variants of the virus that causes COVID-19, 2021. Available: https://www.cdc.gov/coronavirus/2019-ncov/transmission/variant.html

13.

Control CfD . Variant proportions 2021, 2021. Available: https://covid.cdc.gov/covid-data-tracker/#variant-proportions

14.

Rolland

, Gilbert

. Sieve analysis to understand how SARS-CoV-2 diversity can impact vaccine protection. PLoS Pathog 2021;17:e1009406.doi:10.1371/journal.ppat.1009406http://www.ncbi.nlm.nih.gov/pubmed/33765086

15.

CDC . COVID-19 breakthrough case investigations and reporting, 2021. Available: https://www.cdc.gov/vaccines/covid-19/health-departments/breakthrough-cases.html

16.

Dyer

. Covid-19: US reports low rate of new infections in people already vaccinated. BMJ 2021;373:n1000.doi:10.1136/bmj.n1000http://www.ncbi.nlm.nih.gov/pubmed/33863709

17.

Philomina

J B

, Jolly

, John

, . Genomic survey of SARS-CoV-2 vaccine breakthrough infections in healthcare workers from Kerala, India. J Infect 2021;83:237–79.doi:10.1016/j.jinf.2021.05.018http://www.ncbi.nlm.nih.gov/pubmed/34044037

18.

Pollett

, Richard

, Fries

. The SARS-CoV-2 mRNA vaccine breakthrough infection phenotype includes significant symptoms, live virus shedding, and viral genetic diversity. Clin Infect Dis 2022;74:897–900.doi:10.1093/cid/ciab543

19.

Prevention CfDCa . Monitoring incidence of COVID-19 cases, hospitalizations, and deaths, by vaccination status - 13 U.S. jurisdictions, April 4–July 17, 2021, 2021. Available: https://www.cdc.gov/mmwr/volumes/70/wr/mm7037e1.htm?s_cid=mm7037e1_w#T1_down

20.

Prevention CfDCa . CDC COVID data Tracker, 2021. Available: https://covid.cdc.gov/covid-data-tracker/vaccinationsvacc-total-admin-rate-totalAhttps://covid.cdc.gov/covid-data-tracker/vaccinations-pregnant-womenAhttps://covid.cdc.gov/covid-data-tracker/datatracker-homeAhttps://covid.cdc.gov/covid-data-trac

21.

Oran

, Topol

. The proportion of SARS-CoV-2 infections that are asymptomatic. Ann Intern Med 2021;174:1344–5.doi:10.7326/L21-0491http://www.ncbi.nlm.nih.gov/pubmed/34543599

22.

Klompas

. Understanding breakthrough infections following mRNA SARS-CoV-2 vaccination. JAMA 2021;326:2018–20.doi:10.1001/jama.2021.19063http://www.ncbi.nlm.nih.gov/pubmed/34734985

23.

Center JHCR . State breakthrough case data inconsistencies, 2021. Available: https://coronavirus.jhu.edu/pandemic-data-initiative/data-outlook/the-state-of-state-level-breakthrough-case-reporting

24.

Times

TNY

. Covid-19 vaccinations: County and state Tracker, 2021. Available: https://www.nytimes.com/interactive/2020/us/covid-19-vaccine-doses.html

25.

Health VDo . Testing 2021. Available: https://www.healthvermont.gov/covid-19/testing

26.

Bozio

, Grannis

, Naleway

, . Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep 2021;70:1539–44.doi:10.15585/mmwr.mm7044e1http://www.ncbi.nlm.nih.gov/pubmed/34735425

27.

Health RIDo. . Ri department of health COVID-19 response, 2021. Available: https://ri-department-of-health-covid-19-response-vaccine-data-rihealth.hub.arcgis.com/

28.

Massachusetts Co . Massachusetts COVID-19 vaccination data and updates, 2021. Available: https://www.mass.gov/info-details/massachusetts-covid-19-vaccination-data-and-updates

29.

Tenforde

, Self

, Adams

, . Association between mRNA vaccination and COVID-19 hospitalization and disease severity. JAMA 2021;326:2043–54.doi:10.1001/jama.2021.19499http://www.ncbi.nlm.nih.gov/pubmed/34734975

30.

Petter

, Mor

, Zuckerman

. Initial real world evidence for lower viral load of individuals who have been vaccinated by BNT162b2. medRxiv 2021.doi:10.1101/2021.02.08.21251329

31.

Chia

, Ong

SWX

, Chiew

, . Virological and serological kinetics of SARS-CoV-2 delta variant vaccine breakthrough infections: a multicentre cohort study. Clin Microbiol Infect 2022;28:612.e1–612.e7.doi:10.1016/j.cmi.2021.11.010http://www.ncbi.nlm.nih.gov/pubmed/34826623

32.

Nainu

, Abidin

, Bahar

, . SARS-CoV-2 reinfection and implications for vaccine development. Hum Vaccin Immunother 2020;16:3061–73.doi:10.1080/21645515.2020.1830683http://www.ncbi.nlm.nih.gov/pubmed/33393854

33.

Halstead

, Katzelnick

. COVID-19 vaccines: should we fear ade? J Infect Dis 2020;222:1946–50.doi:10.1093/infdis/jiaa518http://www.ncbi.nlm.nih.gov/pubmed/32785649

34.

Elliott

, Haw

, Wang

, . Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the delta variant. Science 2021;374:eabl9551.doi:10.1126/science.abl9551http://www.ncbi.nlm.nih.gov/pubmed/34726481

35.

El Sahly

, Baden

, Essink

, . Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N Engl J Med 2021;385:1774–85.doi:10.1056/NEJMoa2113017http://www.ncbi.nlm.nih.gov/pubmed/34551225

36.

Thomas

, Moreira

, Kitchin

, . Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med 2021;385:1761–73.doi:10.1056/NEJMoa2110345http://www.ncbi.nlm.nih.gov/pubmed/34525277

37.

Tartof

, Slezak

, Fischer

, . Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet 2021;398:1407–16.doi:10.1016/S0140-6736(21)02183-8http://www.ncbi.nlm.nih.gov/pubmed/34619098

38.

de Gier

, Andeweg

, Backer

, . Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominance of delta variant (B.1.617.2), the Netherlands, August to September 2021. Euro Surveill 2021;26.doi:10.2807/1560-7917.ES.2021.26.44.2100977

39.

Kuhlmann

, Mayer

, Claassen

, . Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose. Lancet 2022;399:625–6.doi:10.1016/S0140-6736(22)00090-3http://www.ncbi.nlm.nih.gov/pubmed/35063123

40.

Willyard

. What the omicron wave is revealing about human immunity. Nature 2022;602:22–5.doi:10.1038/d41586-022-00214-3http://www.ncbi.nlm.nih.gov/pubmed/35110764

41.

Callaway

. Omicron likely to weaken COVID vaccine protection. Nature 2021;600:367–8.doi:10.1038/d41586-021-03672-3http://www.ncbi.nlm.nih.gov/pubmed/34880488

42.

Tenforde

, Patel

, Gaglani

, . Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults - United States, August-December 2021. MMWR Morb Mortal Wkly Rep 2022;71:118–24.doi:10.15585/mmwr.mm7104a2http://www.ncbi.nlm.nih.gov/pubmed/35085218

43.

Ramirez

, Wilkes

, Carpi

. . SARS-CoV-2 breakthrough infections in fully vaccinated individuals. MedRxiv 2021.doi:10.1101/2021.06.21.21258990

44.

Hacisuleyman

, Hale

, Saito

, . Vaccine breakthrough infections with SARS-CoV-2 variants. N Engl J Med 2021;384:2212–8.doi:10.1056/NEJMoa2105000http://www.ncbi.nlm.nih.gov/pubmed/33882219

45.

Teran

, Walblay

, Shane

, . Postvaccination SARS-CoV-2 Infections Among Skilled Nursing Facility Residents and Staff Members - Chicago, Illinois, December 2020-March 2021. MMWR Morb Mortal Wkly Rep 2021;70:632–8.doi:10.15585/mmwr.mm7017e1http://www.ncbi.nlm.nih.gov/pubmed/33914721